ESMO 2017 | Maintaining perspective on the implementation of biosimilars

Wojciech Jurczak, MD, PhD, from the Jagiellonian University, Kopernika, Poland talks to us to give his opinion on the potential hazards and safety associated with the use of biosimilars as agents to treat cancer patients. Dr Jurczak feels that while their impact on the economy is an important factor it’s important to maintain perspective, explaining the competition of biosimilars with existing drugs. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.